ERBB2 and triple-negative breast carcinoma: Lapatinib, a tyrosine kinase inhibitor primarily utilized to treat human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer, was observed to induce significant apoptosis and inhibit CIP2A and p-Akt in triple-negative breast cancer cell lines by blocking CIP2A signaling [126].